Key Takeaways PacBio beat first-quarter estimates with higher margins and a narrower adjusted operating loss. PACB's Revio and Vega systems drove adoption across research, clinical, and academic markets. PacBio targets $45 to $50 million in annual cost savings via restructuring by the end of 2025.Pacific Biosciences of California, Inc. (PACB) , popularly known as PacBio, has been gaining from its continued product development. The optimism, led by decent first-quarter results, is expected to contribute fu ...

Financial Data and Key Metrics Changes - The meeting addressed the formal business of the Annual Meeting of Stockholders, including the election of directors and the ratification of the independent registered public accounting firm [5][12] - Preliminary results indicated that the election of directors and the ratification of Ernst and Young LLP were approved [12][13] Business Line Data and Key Metrics Changes - No specific business line data or key metrics were discussed during the meeting [16] Market Data and Key Metrics Changes - No specific market data or key metrics were provided during the meeting [16] Company Strategy and Development Direction and Industry Competition - The board of directors recommended an amendment to the 2020 equity incentive plan to increase the number of shares reserved, which is aimed at attracting and retaining talent [10] Management's Comments on Operating Environment and Future Outlook - Management did not provide specific comments on the operating environment or future outlook during the meeting [16] Other Important Information - The meeting was held virtually in accordance with company bylaws and Delaware law, and the proxy statement was made available to stockholders prior to the meeting [5][6] Q&A Session Summary - There were no questions submitted during the Q&A session [16]

Pacific Biosciences of California (PACB) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Sinc ...

PacBio (PACB) recently announced a key distribution agreement with Haorui Gene, a globally recognized leader in blood typing genomics. This strategic partnership grants PacBio access to a wider clinical laboratory network across China, accelerating the adoption of its HiFi sequencing technology. Haorui Gene, known for its expertise in genomic solutions and extensive reach within the clinical diagnostics ecosystem, will serve as an important channel partner to promote PacBio’s advanced long-read sequencing p ...

Haorui’s established footprint brings HiFi sequencing to new customers including hospital labs and regional blood centersMENLO PARK, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading provider of high-quality, highly accurate sequencing solutions, today announced the appointment of Haorui Gene, a globally recognized leader in blood typing genomics, as an official distributor in China. The distribution arrangement is designed to expand access to PacBio’s HiFi long-read sequencing techn ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ Form 10-Q _____________________________________________________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Core Viewpoint - PacBio has entered a strategic collaboration with Chulalongkorn University to implement its HiFi whole genome sequencing technology in newborn screening, marking a significant advancement in genomic research and public health in the Asia Pacific region [1][4]. Company Summary - The collaboration represents the first population-scale deployment of PacBio's HiFi technology in the Asia Pacific, aimed at improving the identification of rare, treatable conditions in newborns [1][4]. - PacBio's HiFi WGS technology offers a more comprehensive view of the genome, capturing genetic variants that traditional methods may miss, thus enhancing early diagnosis and intervention capabilities [8][10]. - The company currently has a market capitalization of $336.1 million and anticipates earnings growth of 13.1% in 2025 [5]. Industry Summary - The global whole genome sequencing market is projected to reach $2.12 billion in 2024, with an expected compound annual growth rate (CAGR) of 22.17% from 2025 to 2030, driven by technological advancements and increasing demand for personalized medicine [11][12]. - The collaboration positions Thailand as a leader in precision medicine within the Asia Pacific, potentially catalyzing similar initiatives in other countries and expanding PacBio's market presence [10].

MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and ...

Core Insights - PacBio reported an adjusted loss per share of 15 cents for Q1 2025, an improvement from a loss of 26 cents in the same quarter last year, exceeding the Zacks Consensus Estimate by 21.1% [1] - Total revenues for the first quarter were $37.2 million, down 4.3% year over year, but above the Zacks Consensus Estimate by 6.2% [2] - The company experienced a decline in revenues across the Americas and Asia-Pacific regions, while the EMEA region saw an 11% increase in revenues [3][4][5] Revenue Breakdown - Revenues from the Americas were $16.3 million, an 8% decline year over year due to government funding challenges [3] - Asia-Pacific revenues totaled $11.6 million, reflecting a 9% decline, although consumables performed well due to increased utilization of the Revio system [4] - EMEA revenues reached $9.3 million, an 11% increase, driven by strong Revio placements in the hospital and clinic segment [5] Segment Analysis - Total product revenues were $31.1 million, down 11.1% year over year, with instrument revenues significantly impacted, falling 42.1% to $11 million [6] - Consumables revenues increased by 25.6% to $20.1 million, with annualized Revio pull-through per system at $236,000 [7] - Service and other revenues rose 57.9% to $6 million, attributed to increased service contract revenues related to Revio [7] Margin and Expense Trends - Adjusted gross profit increased 18.8% year over year to $15 million, with adjusted gross margin expanding by 700 basis points to 40% [8] - Sales, general, and administrative expenses decreased by 8.2% to $40.2 million, while research and development expenses fell 33.2% to $29.1 million [8] - Total adjusted operating loss was $54.2 million, an improvement from $74.6 million in the prior year [9] Financial Position - At the end of Q1 2025, PacBio had cash and investments totaling $343.1 million, down from $389.9 million at the end of 2024 [10] Guidance and Outlook - For Q2 2025, PacBio expects revenues to be flat compared to Q1 2025, with a Zacks Consensus Estimate of $36.9 million [11] - The company revised its 2025 revenue outlook to between $150 million and $170 million, down from the previous guidance of $155 million to $170 million [12] Strategic Initiatives - PacBio initiated a company-wide restructuring plan aimed at reducing operating expenses by approximately $45 million to $50 million by the end of 2025 [14] - The company entered a licensing agreement to enhance methylation detection capabilities within its HiFi sequencing platform, which is expected to expand applications in cancer research and rare disease diagnostics [15] - Performance was impacted by macroeconomic challenges, including reduced academic funding and U.S.-China tariffs, leading to a decline in Revio system shipments [16]

Core Insights - Pacific Biosciences of California (PACB) reported a revenue of $37.15 million for the quarter ended March 2025, reflecting a decrease of 4.3% year-over-year, but exceeding the Zacks Consensus Estimate by 6.15% [1] - The company's EPS was -$0.15, an improvement from -$0.26 in the same quarter last year, and surpassed the consensus EPS estimate of -$0.19 by 21.05% [1] Revenue Breakdown - Revenue from Product-Instrument was $11 million, falling short of the estimated $12.21 million, marking a significant decline of 42.1% year-over-year [4] - Revenue from Product reached $31.11 million, slightly above the estimated $30.90 million [4] - Revenue from Service and other sources was $6.04 million, exceeding the estimated $4.97 million, representing a substantial increase of 58.9% year-over-year [4] - Revenue from Product-Consumable was $20.10 million, surpassing the average estimate of $18.69 million, with a year-over-year growth of 25.6% [4] Stock Performance - Over the past month, shares of Pacific Biosciences have declined by 22.1%, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]